Remdesivir News and Research

RSS

UH to participate as study site for Pfizer and BioNTech's COVID-19 vaccine

University Hospitals announced today plans to participate as a study site for the Phase 2/3 global study sponsored by Pfizer Inc. and BioNTech SE of an investigational vaccine, BNT162b2, against SARS-CoV-2.

24 Aug 2020

SARS-CoV-2 ORF9c responsible for immune evasion and efficient infection of host

A recent study by researchers at the Sanford Burnham Prebys Medical Discovery Institute and the University of California San Francisco and published on the preprint server bioRxiv in August 2020 shows that a protein encoded by the subgenomic sequence ORF9c of SARS-CoV-2 is responsible for the low antiviral response in infected humans, enabling the successful replication of the virus in the host.

21 Aug 2020

AI can expedite drug repurposing process for finding COVID-19 therapies, says GlobalData

Out of all the different approaches available to find new therapies to treat COVID-19, drug repurposing is one of the fastest and safest methods, as the drugs are already being used to treat other conditions therefore leading to fewer chances of adverse reactions.

21 Aug 2020

Targeting SARS-CoV-2 with off-the-shelf CAR-NK cells

The current COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread and cause disease and death in many countries even today. At present, there is no effective treatment. A recent study published on the preprint server bioRxiv in August 2020 reports the potential of a new class of drugs called CAR NK cells, which could be used off-the-shelf to treat this disease.

17 Aug 2020

Machine learning helps detect new potential drugs to treat COVID-19

Scientists at the University of California, Riverside, have used machine learning to identify hundreds of new potential drugs that could help treat COVID-19, the disease caused by the novel coronavirus, or SARS-CoV-2.

12 Aug 2020

Novel strategy provides new hope to fight COVID-19

A novel strategy has been developed by Novateur Ventures, which provides new hope in battle against COVID-19. The study titled 'A Novel Strategy to Mitigate the Hyperinflammatory Response to COVID-19 by Targeting Leukotrienes' was published in Frontiers in Pharmacology, a leading peer-reviewed journal.

12 Aug 2020

People of color, minority groups are underrepresented in COVID-19 clinical trials

Despite disproportionately higher rates of COVID-19 infection, hospitalization and death among people of color, minority groups are significantly underrepresented in COVID-19 clinical trials, according to a new perspective authored by faculty from the University of Georgia and University of Colorado and pharmacists from Phoebe Putney Memorial Hospital in Albany.

11 Aug 2020

Baylor Scott & White Research Institute enrolls first patients in NIH ACTIV-3 clinical trial

On Wednesday, August 5, in Dallas, just one day after the initiative was launched by the National Institutes of Health, Baylor Scott & White Research Institute enrolled the first patient in the world for the ACTIV-3 clinical trial. A second patient was enrolled the following day.

10 Aug 2020

Study: Drinking honeysuckle decoction accelerates the negative conversion of COVID-19 patients

In a new study in Cell Discovery, Chen-Yu Zhang's group at Nanjing University and two other groups from Wuhan Institute of Virology and the Second Hospital of Nanjing present a novel finding that absorbed miRNA MIR2911 in honeysuckle decoction (HD) can directly target SARS-CoV-2 genes and inhibit viral replication. Drinking of HD accelerate the negative conversion of COVID-19 patients.

7 Aug 2020

Interleukin-6 inhibitors appear to be a more effective treatment for COVID-19

New research from Boston Medical Center found that patients experiencing severe COVID-19 symptoms had improved outcomes when administered an Interleukin-6 (IL6ri) inhibitor, sarilumab or tocilizumab, given to mediate severe systemic inflammatory responses.

5 Aug 2020

Clinical trial to test safety, efficacy of antibody treatment in hospitalized COVID-19 patients

Patients admitted with COVID-19 at select hospitals may now volunteer to enroll in a clinical trial to test the safety and efficacy of a potential new treatment for the disease.

4 Aug 2020

Yale and AI Therapeutics launch clinical trial of potential COVID-19 drug

Yale School of Medicine and the biopharmaceutical firm AI Therapeutics have launched a multi-institutional clinical trial of a drug for treating COVID-19.

27 Jul 2020

Seaweed extract outperforms remdesivir in inhibiting SARS-CoV-2 in cell studies

In a test of antiviral effectiveness against the virus that causes COVID-19, an extract from edible seaweeds substantially outperformed remdesivir, the current standard antiviral used to combat the disease.

24 Jul 2020

Compelling study shows heparin may protect against COVID-19

A compelling new study conducted by an international team of researchers has demonstrated that the widely used blood-thinning medication - heparin - can block infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent that causes coronavirus disease 2019 (COVID-19).

16 Jul 2020

Researcher and health research journalist point out biased misinformation on coronavirus

In a new JAMA editorial, a Boston University School of Public Health (BUSPH) researcher and a health research journalist outline common ways that media, governments, and industry and academic public relations press releases have incompletely and misleadingly reported coronavirus research, and how they can do better.

14 Jul 2020

People with accelerated biological age at increased risk of COVID-19 symptom severity and mortality

Now, a new study published on the preprint server medRxiv in July 2020 discusses the explanation in terms of the biological aging markers in patients with severe disease, rather than the chronological age.

13 Jul 2020

COVID-19 – researchers sum up the “Tsunami” of information

The severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) infection leading to COVID-19 is a raging pandemic across the world at present. It has infected 13 million and killed 571,000 individuals around the world as of today. The infection was first reported in Wuhan, Hubei Province of China in late December 2019.

13 Jul 2020

Study identifies three novel broad-spectrum SARS-CoV-2 cell entry inhibitors

Researchers from the National Institutes of Health (NIH) and Cornell University in the U.S. just described several new inhibitors of human coronavirus spike proteins by screening a library of approved drugs with SARS-S and MERS-S pseudotyped particle entry assays. Their exciting findings are currently available on the bioRxiv preprint server.

13 Jul 2020

Remdesivir potently inhibits SARS-CoV-2 in human lung cell cultures

The news about remdesivir, the investigational anti-viral drug that has shown early promise in the fight against COVID-19, keeps getting better.

9 Jul 2020

SARS-CoV-2 a dagger to the aging heart

Researchers in Europe have shown that genes involved in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are expressed to a higher degree in older heart muscle cells (cardiomyocytes) than they are in younger cardiomyocytes.

9 Jul 2020